Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of Growth and Induction of Differentiation of SMMC-7721 Human Hepatocellular Carcinoma Cells by Oncostatin M

  • Kong, N. (Department of Regenerative Medicine, College of Pharmacy, Jilin University) ;
  • Zhang, X.M. (Department of Regenerative Medicine, College of Pharmacy, Jilin University) ;
  • Wang, H.T. (Department of Regenerative Medicine, College of Pharmacy, Jilin University) ;
  • Mu, X.P. (Laboratory of Tang Ao-qing, China-Japan Union Hospital, Jilin University) ;
  • Han, H.Z. (Journal of Jilin University Medicine Edition, Jilin University) ;
  • Yan, W.Q. (Department of Regenerative Medicine, College of Pharmacy, Jilin University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Oncostatin M (OSM) is a multifunctional cellular regulator acting on a wide variety of cells, which has potential roles in the regulation of gene activation, cell survival, proliferation and differentiation. Previous studies have shown that OSM can induce morphological and/or functional differentiation and maturation of many tumor cells. However, the action of OSM on the induction of differentiation of human hepatocellular carcinoma (HCC) has not been reported. Here, we investigated the effects of different concentrations of OSM on human HCC cell line SMMC-7721 growth, proliferation, cell cycling, apoptosis and differentiation in vitro. Cell growth was determined via MTT assay, proliferation by cell cycle analysis, apoptosis by flow cytometry, morphology by transmission electronic microscopy, and cell function by detection of biochemical markers. Our results demonstrated that OSM strongly inhibited the growth of SMMC-7721 cells in a dose-dependent manner, associated with decreased clonogenicity. Cell cycle analysis revealed a decreased proportion of cells in S phase, with arrest at G0/G1. The apotosis rate was increased after OSM treatment compared to the control. These changes were associated with striking changes in cellular morphology, toward a more mature hepatic phenotype, accompanied by significant reduction of the expression of AFP and specific activity of ${\gamma}$-GT, with remarkable increase in secretion of albumin and ALP activity. Taken together, our findings indicate that OSM could induce the differentiation and reduce cell viability of SMMC-7721 cells, suggesting that differentiation therapy with OSM offers the opportunity for therapeutic intervention in HCC.

Keywords

References

  1. Blais ME, Louis I, Perreault C (2006). T-cell development: an extrathymic perspective. Immunol Rev, 209, 103-14. https://doi.org/10.1111/j.0105-2896.2006.00341.x
  2. Brounais B, David E, Chipoy C, et al (2009). Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 44, 830-9. https://doi.org/10.1016/j.bone.2008.12.021
  3. Bruce AG, Hoggatt IH, Rose TM (1992). Oncostatin M is a differentiation factor for myeloid leukemia cells. J Immunol, 149, 1271-5.
  4. Chen SH, Gillespie GY, Benveniste EN (2006). Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia, 53, 191-200. https://doi.org/10.1002/glia.20264
  5. Damdinsuren B, Nagano H, Kondo M, et al (2006). TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells. Oncol Rep, 15, 401-8.
  6. Guan YS (2006). Hepatocellular carcinoma: the curative attempts. J US-China Med Sci, 3, 59-71.
  7. Halfter H, Friedrich M, Resch A, et al (2006). Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res, 66, 6530-9. https://doi.org/10.1158/0008-5472.CAN-04-3734
  8. Hamada T, Sato A, Hirano T, et al (2007). Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. Am J Pathol, 171, 872-81. https://doi.org/10.2353/ajpath.2007.060972
  9. Hay DC, Zhao D, Fletcher J, et al (2008). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells, 26, 894-902. https://doi.org/10.1634/stemcells.2007-0718
  10. Kamiya A, Gonzalez FJ, Nakauchi H (2006). Identification and differentiation of hepatic stem cells during liver development. Front Biosc, 11, 1302-10. https://doi.org/10.2741/1884
  11. Kinoshita T, Miyajima A (2002). Cytokine regulation of liver development. Biochim Biophys Acta, 1592, 303-12. https://doi.org/10.1016/S0167-4889(02)00323-3
  12. Kong N, Mu X, Han H, et al (2009). Pilot-scale fermentation, purification, and characterization of recombinant human oncostatin M in pichia pastoris. Protein Expr Purif, 63, 134-9. https://doi.org/10.1016/j.pep.2008.10.002
  13. Kong WJ, Abidi P, Kraemer FB, et al (2005). In vivo activities of cytokine oncostatin M in regulation of plasma lipid levels. J Lipid Res, 46, 1163-71. https://doi.org/10.1194/jlr.M400425-JLR200
  14. Li WQ, Dehnade F, Zafarullah M (2001). Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol, 166, 3491-8. https://doi.org/10.4049/jimmunol.166.5.3491
  15. Luyckx VA, Cairo LV, Compston CA, et al (2009). Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol, 296, 875-83. https://doi.org/10.1152/ajprenal.90633.2008
  16. Masaki T, Shiratori Y, Rengifo W, et al (2003). Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology, 37, 534-43. https://doi.org/10.1053/jhep.2003.50112
  17. McCormick C, Freshney RI (2000). Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma. Br J Cancer, 82, 881-90. https://doi.org/10.1054/bjoc.1999.1015
  18. Morikawa Y (2005). Oncostatin M in the development of the nervous system. Anat Sci Int, 80, 53-9. https://doi.org/10.1111/j.1447-073x.2005.00100.x
  19. Okaya A, Kitanaka J, Kitanaka N, (2005). Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes. Am J Pathol, 166, 709-19. https://doi.org/10.1016/S0002-9440(10)62292-4
  20. Sensken S, Waclawczyk S, Knaupp AS (2007). In vitro differentiation of human cord blood-derived unrestricted somatic stem cells towards an endodermal pathway. Cytotherap, 9, 362-78. https://doi.org/10.1080/14653240701320254
  21. Silver JS, Hunter CA ( 2010). gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol, 88, 1145-56. https://doi.org/10.1189/jlb.0410217
  22. Sims NA, Walsh NC (2010). GP130 cytokines and bone remodelling in health and disease. BMB Rep, 43, 513-23. https://doi.org/10.5483/BMBRep.2010.43.8.513
  23. Song HY, Jeon ES, Jung JS (2005). Oncostatin M induces proliferation of human adipose tissue-derived mesenchymal stem cells. Int J Biochem Cell Biol, 37, 2357-65 https://doi.org/10.1016/j.biocel.2005.05.007
  24. Tanaka M, Miyajima A (2003). Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol, 149, 39-52.
  25. Wang CT, Meng M, Zhang JC (2008). Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate. Chin Med J (Engl), 121, 1707-11.
  26. Wei X, Wang CY, Liu QP (2008). In vitro hepatic differentiation of mesenchymal stem cells from human fetal bone marrow. J Int Med Res, 36, 721-7. https://doi.org/10.1177/147323000803600414
  27. Weiss TW, Samson AL, Niego B, et al (2006). Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J, 20, 2369-71. https://doi.org/10.1096/fj.06-5850fje
  28. West NR, Murphy LC, Watson PH (2012). Oncostatin M suppresses oestrogen receptor-$\alpha$ expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer, 19, 181-95. https://doi.org/10.1530/ERC-11-0326
  29. Yamashita Y, Shimada M, Harimoto N, et al (2003). Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer, 103, 572-6. https://doi.org/10.1002/ijc.10699
  30. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8. https://doi.org/10.7314/APJCP.2012.13.11.5433
  31. Zeng XL, Tu ZG (2003). In vitro induction of differentiation by Ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line. Pharmacol Toxicol, 93, 275-83. https://doi.org/10.1111/j.1600-0773.2003.pto930605.x

Cited by

  1. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
  2. Molecular Mechanisms Underlying Antiproliferative and Differentiating Responses of Hepatocarcinoma Cells to Subthermal Electric Stimulation vol.9, pp.1, 2014, https://doi.org/10.1371/journal.pone.0084636
  3. Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients vol.32, pp.4, 2017, https://doi.org/10.5301/ijbm.5000300